The European Union's drug regulator said Tuesday it has begun an accelerated review process for an experimental coronavirus vaccine booster made by the Spanish company Hipra.
The European Medicines Agency said in a statement that its evaluation is based on preliminary data from laboratory studies and research in adults that compared Hipra's booster shot to the vaccine made by Pfizer-BioNTech. It said early results suggest the immune response achieved with Hipra “may be effective” against COVID-19, including the hugely infectious omicron variant.
